// App-Quantinova.ai

: Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

Researchers

Presenter

  • Jordan Gauthier

Principal Investigators

  • Alexandre V. Hirayama

  • Kevin A. Hay

  • Alyssa Sheih

  • Barbara S. Pender

  • Reed M. Hawkins

  • Aesha Vakil

  • Tinh-Doan Phi

  • Rachel N. Steinmetz

  • Aude G. Chapuis

  • Brian G. Till

  • Hans-Peter Kiem

  • Mazyar Shadman

  • Ryan D. Cassaday

  • Utkarsh H. Acharya

  • Stanley R. Riddell

  • David G. Maloney

  • Cameron J. Turtle

Medical Centers

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

  • Dept of Medicine, Univ of Washington, Seattle, WA

  • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • B-Cell Non-Hodgkin Lymphoma

  • Cytokine release syndrome

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

  • Cytokine

  • Twist-related protein 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT03103971

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved